Subcutaneous Tirzepatide Once-weekly in Patients With Obesity and Knee Osteoarthritis (STOP KNEE-OA)

ClinicalTrials.gov ID

NCT06191848

Lead Sponsor

University of MelbourneOTHER

Overall Status

Recruiting

Study Type

Interventional

Phase

Phase 4

Enrollment

352Estimated

Last Update Posted

Apr 30, 2025Actual

Start Date

Nov 19, 2024Actual

Primary Completion Date

May 2027Estimated

Completion Date

May 2037Estimated

Official Title

Effect of Subcutaneous Tirzepatide Once-weekly in Patients With Obesity and Knee Osteoarthritis (STOP KNEE-OA): A Randomized, Double-Blind, Placebo-Controlled Trial

Brief Summary

This is a trial of tirzepatide in people with obesity and knee osteoarthritis. The main purpose of this study is to see if tirzepatide can reduce number of these participants who require a knee replacement. Participants will be randomized to take a weekly injection of tirzepatide or a placebo for a total of 72 weeks.

• Obesity
• Knee Osteoarthritis
• Osteoarthritis, Knee

• Tirzepatide
• Placebo

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• Have a body mass index of ≥ to 30 kg/m2.
• Report one or more previous unsuccessful attempt to lose body weight via lifestyle modification.
• Have been deemed eligible to enter the waiting list for primary knee replacement for the treatment of osteoarthritis in the target joint by an orthopaedic surgeon at one of the participating study sites.
• Have moderate-to-severe knee osteoarthritis in the target joint, defined as a Kellgren-Lawrence grade two or greater.
• Be willing to and capable of learning how to self-inject the study drug and follow study procedures for the duration of the trial.
• Provide informed consent to study participation in line with the requirements of the human research ethics committee of the study site.

Female participants must:

• Not be currently pregnant or breastfeeding AND
• Not be of reproductive potential, defined as:
• Infertile due to surgical sterilization or congenital anomaly, OR
• Post-menopausal defined as:
• A woman over the age of 40 years with spontaneous cessation of menses for at least 12 consecutive months (in the absence of medications known to induce amenorrhea), with a follicle-stimulating hormone ≥40mIU/mL, and a negative pregnancy test prior to study entry, OR
• A woman over the age of 55 years with cessation of menses for at least 12 consecutive months (in the absence of medications known to induce amenorrhea), OR
• A woman over the age of 55 years that has commenced hormone replacement therapy after a documented diagnosis of menopause.

Exclusion Criteria:

Participant will be ineligible for inclusion if they meet any of the following criteria:

• Have been deemed eligible to enter the waiting list for knee replacement in the contralateral knee by an orthopaedic surgeon at one of the participating study sites.

• Have used any prescription medications intended to promote weight loss (e.g., tirzepatide, liraglutide, semaglutide) in the three months prior to screening.

• Have previously undergone any surgical or endoscopic procedure intended to promote weight loss.

• Have been diagnosed with type 1 diabetes mellitus (T1DM) or T2DM

• Have laboratory evidence indicative of diabetes mellitus during screening.

• Have personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)

• Have an active malignancy (excluding basal or squamous cell skin cancer).

• Have had a transplanted organ or awaiting an organ transplant

• Have received chronic systemic glucocorticoid therapy (for more than 14 days) in prior 3 months or have a significant, active autoimmune abnormality (e.g., lupus or rheumatoid arthritis) that the study doctor deems likely to require systemic glucocorticoid therapy during the next 18 months.

• Have any other medical conditions, abnormal laboratory tests or concomitant medications that make them unsuitable for participation:

  • Have a clinically significant gastric emptying abnormality.
  • Have had a history of acute or chronic pancreatitis.
  • Have obesity induced by other endocrinologic disorders
  • Have an unstable psychiatric disorder
  • Have a Patient Health Questionnaire (PHQ-9) score of >15 during screening
  • Have been deemed by the study doctor to be actively suicidal,

• Have answered "yes" to questions 4 or 5 on the "Suicidal Ideation" section of the Columbia-Suicide Severity Rating Scale (C-SSRS) during screening, OR

• Have answered yes to any questions in the "Suicidal Behaviour" section of the C-SSRS during screening. AND

• The behaviour or ideation occurred in the last month

  • Have uncontrolled hypertension (systolic blood pressure above or equal to 160 mmHg and/or diastolic blood pressure above or equal to 100 mmHg)
  • Have had within the past 6 months prior to randomisation any of the following: acute myocardial infarction, cerebrovascular accident, unstable angina, or hospitalisation due to congestive cardiac failure (are also exclusion criteria for elective knee replacement)
  • Have severe renal impairment defined as an eGFR <30 mL/min/1.73 m2 at screening visit.
  • Have thyroid-stimulating hormone outside of the range of 0.4 to 6.0 mIU/L at screening visit
  • Have acute or chronic hepatitis or abnormal liver function tests as measured by either alanine aminotransferase or alkaline phosphatase >200 IU.
  • Have any other known contraindication to any glucagon-like peptide-1 receptor agonists.

• Are study site personnel, or immediate family of a member of the study site.

• Have been enrolled in any other study of an investigational product within the past ninety days or are currently enrolled in such a study.

Primary Purpose

Treatment

Allocation

Randomized

Interventional Model

Parallel Assignment

Masking

Quadruple

Lead Sponsor

University of MelbourneOTHER

Collaborators

Eli Lilly and CompanyINDUSTRY

libby.spiers@wh.org.au+61 03 8345 6666

sallie.castleman3@easternhealth.org.au+61 03 9871 3159

• A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee

  NCT05931367

  CompletedInterventionalPhase 3Updated Jan 21, 2026
• A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight

  NCT06914895

  Active, not recruitingInterventionalPhase 3Updated May 12, 2026
• A Study to Measure Energy Expenditure and Food Intake in Participants With Obesity Using Tirzepatide

  NCT04081337

  CompletedInterventionalPhase 1Updated Feb 8, 2024
• Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity

  NCT05912621

  RecruitingInterventionalPhase 2Updated Dec 4, 2024
• A Study of Tirzepatide (LY3298176) in Participants With Obesity Disease

  NCT04844918

  CompletedInterventionalPhase 3Updated Jul 16, 2024
• A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight

  NCT04184622

  CompletedInterventionalPhase 3Updated Jul 24, 2025